Abstract
Abstract Background Therapy for alopecia areata (AA) in a pediatric patient population is challenging and controversial. Common treatments include a variety of topical or injected agents. Systemic steroid treatment in children is controversial due to concern of negative side effects. The purpose of this study was to evaluate the efficacy and safety of systemic corticosteroid therapy for the treatment of AA in pediatric patients. Methods This retrospective chart review included patients treated with standard courses of oral corticosteroids (3-week taper starting at 1 mg/kg) for AA who were managed by the Dermatology Section at the Children's Hospital of Philadelphia between 2015 and 2018. The following data was extracted from patients' charts: Severity of disease measured by Severity of Alopecia Tool (SALT) scores for AA, treatment regimen, duration of treatment and number of steroid courses, side effects, age, gender, and weight percentiles. SALT scores and weight percentiles were recorded at pretreatment as well as at 3 months and 6 months after initiation of treatment. SALT scores, when available, were additionally recorded at 9, 12, and 15 months after initiation of treatment. Results 82 pediatric subjects were included in the study. Subjects were grouped according to severity at pretreatment with systemic corticosteroids with < 50% SALT as mild and > 50% SALT as Severe. Subjects in the > 50% SALT score group followed at 5 intervals (pre-treatment, 3 months, 6 months, 9 months, 12 months, 15 months) showed statistically-significant improvement/lowering of SALT scores, while subjects in the < 50% SALT group did not over the same time period. No serious adverse side effects were documented in any subjects treated. However, 67 patients of a total of 82 studied relapsed during the time intervals observed. The average time to relapse was 21.9 weeks after initiation of treatment (standard deviation: 16.76 weeks; range: 4.71 to 73.43 weeks; median: 15.43 weeks). Additionally, weight percentiles had a statistically significant increase from baseline. Conclusion Patients with baseline SALT scores ≥ 50 improved significantly after a course of systemic steroids but relapsed on average 4-5 months later with concomitant weight gain.
Highlights
Alopecia areata (AA) is a chronic disease in which T-cell mediated autoimmune processes cause non-scarring patchy hair loss [1]
We examine change in Severity of Alopecia Tool Score as well as time to relapse and secondary side effects
Because of the study’s retrospective design, time points for follow-up measurement correspond to an approximate time of: 0, 12, 24, 36, 60, and 72 weeks, which have been annotated as time T0, T1, T2, T3, T4, and T5, respectively
Summary
Alopecia areata (AA) is a chronic disease in which T-cell mediated autoimmune processes cause non-scarring patchy hair loss [1]. It has been previously reported that AA’s lifetime incidence is approximately 1.7% worldwide, but more recent studies estimate it to be approximately 2.1% [3,4,5]. In the United States between the years 1990 and 2000, this amounted to 2.4 million office visits related to AA [6]. This autoimmune disease increases the risk for depression and anxiety [3]. Therapy for alopecia areata (AA) in a pediatric patient population is challenging and controversial. Systemic steroid treatment in children is controversial due to concern of negative side effects. The purpose of this study was to evaluate the efficacy and safety of systemic corticosteroid therapy for the treatment of AA in pediatric patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
